Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
AL101 is the company’s second product candidate designed to increase the level of progranulin in the human brain. Progranulin has been identified as a key regulator of microglial function in the brain with strong genetic links to multiple …